In August 2012, the DHVI was awarded a grant by the Bill and Melinda Gates Foundation to establish a Protein Production Facility, which is directed by Larry Liao, MD, PhD. The facility is equipped to produce and purify, at cost via subcontract, HIV-1 Env proteins as standardized in vitro reagents that can be used in HIV vaccine research. These reagents are intended to optimize clinical trial immune monitoring and facilitate Env immunogen discovery; however, the proteins are not intended for use in humans or in clinical trials. All of the proteins will be produced under “GxP” best practices, which encompass the applicable elements of Good Manufacturing Practice (GMP), Good Clinical Laboratory Practice (GCLP), and Good Laboratory Practice (GLP) guidelines.